These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1947 related items for PubMed ID: 9749478

  • 1. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
    D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A.
    JAMA; 1998 Sep 16; 280(11):969-74. PubMed ID: 9749478
    [Abstract] [Full Text] [Related]

  • 2. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
    D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
    Cancer; 2002 Jul 15; 95(2):281-6. PubMed ID: 12124827
    [Abstract] [Full Text] [Related]

  • 3. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2002 Mar 01; 52(3):664-73. PubMed ID: 11849788
    [Abstract] [Full Text] [Related]

  • 4. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA, Stock RG, Stone N.
    Int J Radiat Oncol Biol Phys; 2003 Nov 01; 57(3):645-53. PubMed ID: 14529768
    [Abstract] [Full Text] [Related]

  • 5. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E.
    Cancer J Sci Am; 1997 Nov 01; 3(2):78-87. PubMed ID: 9099457
    [Abstract] [Full Text] [Related]

  • 6. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D'Amico AV.
    BJU Int; 2012 Oct 01; 110(8):1116-21. PubMed ID: 22540922
    [Abstract] [Full Text] [Related]

  • 7. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.
    D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA, Kantoff PW.
    JAMA; 2000 Sep 13; 284(10):1280-3. PubMed ID: 10979115
    [Abstract] [Full Text] [Related]

  • 8. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Mar 01; 61(3):714-24. PubMed ID: 15708249
    [Abstract] [Full Text] [Related]

  • 9. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA, Buchsbaum JC, Elshaikh MA, Reddy CA, Klein EA.
    Int J Radiat Oncol Biol Phys; 2003 Nov 01; 57(3):629-34. PubMed ID: 14529766
    [Abstract] [Full Text] [Related]

  • 10. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):415-9. PubMed ID: 15667961
    [Abstract] [Full Text] [Related]

  • 11. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A.
    Lancet Oncol; 2014 Sep 01; 15(10):1076-89. PubMed ID: 25130995
    [Abstract] [Full Text] [Related]

  • 12. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 13. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA, Buchsbaum JC, Elshaikh M, Reddy CA, Zippe C, Klein EA.
    Cancer; 2002 Dec 01; 95(11):2302-7. PubMed ID: 12436435
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy.
    Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA.
    J Clin Oncol; 2002 Aug 15; 20(16):3376-85. PubMed ID: 12177097
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
    Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CAF, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM.
    Cancer; 2017 Jul 01; 123(13):2489-2496. PubMed ID: 28323339
    [Abstract] [Full Text] [Related]

  • 16. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.
    Stokes SH.
    Int J Radiat Oncol Biol Phys; 2000 Apr 01; 47(1):129-36. PubMed ID: 10758314
    [Abstract] [Full Text] [Related]

  • 17. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, Briganti A.
    Eur Urol; 2016 Jun 01; 69(6):1142-8. PubMed ID: 26749093
    [Abstract] [Full Text] [Related]

  • 18. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?
    Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.
    BJU Int; 2003 Jan 01; 91(1):23-9. PubMed ID: 12614244
    [Abstract] [Full Text] [Related]

  • 19. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?
    Keyser D, Kupelian PA, Zippe CD, Levin HS, Klein EA.
    Int J Radiat Oncol Biol Phys; 1997 Jul 01; 38(4):723-9. PubMed ID: 9240638
    [Abstract] [Full Text] [Related]

  • 20. A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution.
    Martinez AA, Gonzalez JA, Chung AK, Kestin LL, Balasubramaniam M, Diokno AC, Ziaja EL, Brabbins DS, Vicini FA.
    Cancer; 2000 Jan 15; 88(2):425-32. PubMed ID: 10640977
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 98.